Cardiac Resynchronization Therapy:. Device-Based Medicine for Heart Failure

Cardiac resynchronization therapy (CRT) or biventricular pacing is a novel adjunctive therapy for patients with advanced heart failure (HF). Many patients with severe HF have a left bundle branch block or an intraventricular conduction delay, with up to 25% of patients with a QRS > 120 ms, resulting in significant left ventricular (LV) dyssynchrony and a high mortality rate. The efficacy of CRT is based on the reduction in the conduction delay between the two ventricles and optimization of the ejection fraction, decrement in mitral regurgitation, LV remodeling, thus resulting in symptom improvement. Cardiac resynchronization therapy can be achieved both transvenously using a coronary sinus branch, or epicardially. Clinical trials have demonstrated a significant improvement in the NYHA class and the exercise capacity as well as a marked reduction in the hospitalization rate. More recently, the COMPANION trial showed a 43% reduction in a composite endpoint of all-cause mortality and hospitalization in the group receiving a CRT device in combination with an implantable cardiac defibrillator (ICD). Thus, management of patients with reduced LV function, wide QRS, and symptomatic refractory HF, despite optimal drug therapy, should include CRT as an option. The adjunct of an ICD combined with CRT should be considered if the LV ejection fraction (ischemic cardiomyopathy) is <30%. There are still significant unanswered questions regarding the nonresponder population and the role of tissue Doppler imaging techniques, the impact of CRT on total mortality and CRT in dilated cardiomyopathy or chronic atrial fibrillation. The use CRT postoperatively or at time of cardiac surgery, as well as new epicardial approaches using a thoracoscopic approach or robotically assisted surgery in patients not suitable for coronary vein leads are challenging topics to address in the years to come.